- Home
- EM vs CKPT Comparison
EM vs CKPT Comparison
Compare EM & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EM
- CKPT
- Stock Information
- Founded
- EM 2017
- CKPT 2014
- Country
- EM China
- CKPT United States
- Employees
- EM N/A
- CKPT N/A
- Industry
- EM Other Consumer Services
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- EM Consumer Discretionary
- CKPT Health Care
- Exchange
- EM Nasdaq
- CKPT Nasdaq
- Market Cap
- EM 191.0M
- CKPT 214.4M
- IPO Year
- EM 2021
- CKPT 2017
- Fundamental
- Price
- EM $0.69
- CKPT $3.61
- Analyst Decision
- EM Strong Buy
- CKPT Strong Buy
- Analyst Count
- EM 1
- CKPT 3
- Target Price
- EM $1.00
- CKPT $10.33
- AVG Volume (30 Days)
- EM 62.2K
- CKPT 2.4M
- Earning Date
- EM 12-31-2024
- CKPT 11-12-2024
- Dividend Yield
- EM N/A
- CKPT N/A
- EPS Growth
- EM N/A
- CKPT N/A
- EPS
- EM 0.03
- CKPT N/A
- Revenue
- EM $269,745,696.00
- CKPT $47,000.00
- Revenue This Year
- EM N/A
- CKPT N/A
- Revenue Next Year
- EM $6.16
- CKPT $151,162.55
- P/E Ratio
- EM $22.06
- CKPT N/A
- Revenue Growth
- EM N/A
- CKPT N/A
- 52 Week Low
- EM $0.43
- CKPT $1.38
- 52 Week High
- EM $1.18
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- EM 55.32
- CKPT 41.64
- Support Level
- EM $0.73
- CKPT $2.98
- Resistance Level
- EM $0.83
- CKPT $4.44
- Average True Range (ATR)
- EM 0.04
- CKPT 0.42
- MACD
- EM 0.00
- CKPT -0.10
- Stochastic Oscillator
- EM 48.57
- CKPT 25.66
About EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging service through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Through the mini-programs, users rent the power banks to carry with them when use the service and can return the power banks at any of the POIs, enabled by the expansive network and powerful technologies.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.